AI Engines For more Details: Perplexity Kagi Labs You
Antioxidant Activity: Nobiletin exhibits strong antioxidant properties, meaning it can neutralize harmful free radicals in the body. Free radicals are unstable molecules that can damage cells and contribute to aging and various diseases. By scavenging free radicals, nobiletin helps to protect cells from oxidative stress and reduce the risk of oxidative damage to tissues throughout the body.
Anti-inflammatory Effects: Nobiletin has been shown to possess anti-inflammatory properties, meaning it can reduce inflammation in the body. Chronic inflammation is associated with the development and progression of various diseases, including cardiovascular disease, neurodegenerative diseases, and cancer. By inhibiting inflammatory pathways and reducing the production of inflammatory molecules, nobiletin may help to alleviate symptoms and slow the progression of these diseases.
Cardiovascular Health: Nobiletin may have beneficial effects on cardiovascular health. It helps to improve endothelial function, reduce inflammation in blood vessels, and inhibit the formation of blood clots. Nobiletin may also help to lower cholesterol levels and blood pressure, reducing the risk of cardiovascular diseases such as atherosclerosis, hypertension, and heart disease.
Metabolic Health: Nobiletin has been studied for its potential benefits in improving metabolic health and preventing obesity and type 2 diabetes. It helps to regulate glucose metabolism, improve insulin sensitivity, and reduce lipid accumulation in adipose tissue and the liver. Nobiletin may also help to suppress appetite and promote weight loss.
Neuroprotective Effects: Nobiletin has been investigated for its potential neuroprotective effects in the brain. It helps to protect neurons from oxidative damage, reduce inflammation, and modulate signaling pathways involved in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Nobiletin may also help to improve cognitive function and memory.
Cancer Prevention: Nobiletin has been studied for its potential anti-cancer properties. It helps to inhibit the growth of cancer cells, induce apoptosis (programmed cell death), and prevent the spread of cancerous tumors. Nobiletin may also help to reduce the risk of cancer by modulating signaling pathways involved in cell growth, proliferation, and survival. It has been studied in various types of cancer, including breast, prostate, lung, colon, and skin cancer.
Liver Health: Nobiletin has been shown to have hepatoprotective effects, meaning it can protect the liver from damage caused by toxins, alcohol, and other harmful substances. It helps to improve liver function, reduce inflammation, and promote liver regeneration. Nobiletin may also help to prevent or alleviate liver diseases such as fatty liver disease, hepatitis, and liver fibrosis.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| Taxonomy | Rank | Effect | Citations | Notation |
|---|---|---|---|---|
| Erysipelotrichaceae | family | Increases | 👪 Source Study | |
| Lachnospiraceae | family | Increases | 👪 Source Study | |
| Allobaculum | genus | Increases | 📓 Source Study | |
| Roseburia | genus | Increases | 📓 Source Study | |
| environmental samples | no rank | Increases | 👶 Source Study | |
| unclassified Allobaculum | no rank | Increases | 👶 Source Study | |
| unclassified Roseburia | no rank | Increases | 👶 Source Study | |
| Allobaculum mucilyticum | species | Increases | 👶 Source Study | |
| Allobaculum stercoricanis | species | Increases | 👶 Source Study | |
| Roseburia cecicola | species | Increases | 👶 Source Study | |
| Roseburia faecis | species | Increases | 👶 Source Study | |
| Roseburia hominis | species | Increases | 👶 Source Study | |
| Roseburia intestinalis | species | Increases | 👶 Source Study | |
| Roseburia inulinivorans | species | Increases | 👶 Source Study | |
| Roseburia porci | species | Increases | 👶 Source Study | |
| Roseburia rectibacter | species | Increases | 👶 Source Study | |
| Roseburia yibonii | species | Increases | 👶 Source Study | |
| Roseburia zhanii | species | Increases | 👶 Source Study |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.9 | 0.9 | |
| ADHD | 0.3 | 0.6 | -1 |
| Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.6 | -1 |
| Allergies | 0.3 | 0.6 | -1 |
| Allergy to milk products | 0.3 | -0.3 | |
| Alopecia (Hair Loss) | 0.6 | -0.6 | |
| Alzheimer's disease | 1.4 | 0.3 | 3.67 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | 0 |
| Ankylosing spondylitis | 0.3 | 0.3 | 0 |
| Anorexia Nervosa | 1.1 | 1.1 | |
| Antiphospholipid syndrome (APS) | 0.2 | -0.2 | |
| Asthma | 0.8 | 0.3 | 1.67 |
| Atherosclerosis | 0.8 | 0.8 | |
| Autism | 1.2 | 1.2 | 0 |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| Bipolar Disorder | 0.6 | 0.6 | |
| Brain Trauma | 0.6 | 0.6 | |
| Celiac Disease | 0.3 | -0.3 | |
| Cerebral Palsy | 0.6 | 0.6 | |
| Chronic Fatigue Syndrome | 0.5 | 0.5 | |
| Chronic Kidney Disease | 0.9 | 0.9 | |
| Chronic Lyme | 0.6 | 0.6 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 0.3 | 1 |
| Coagulation / Micro clot triggering bacteria | 0.6 | 0.6 | |
| Colorectal Cancer | 0.3 | 1.2 | -3 |
| Constipation | 0.6 | 0.3 | 1 |
| Coronary artery disease | 0.3 | 0.3 | 0 |
| COVID-19 | 1.1 | 0.6 | 0.83 |
| Crohn's Disease | 0.9 | 0.8 | 0.13 |
| cystic fibrosis | 0.6 | 0.6 | |
| deep vein thrombosis | 0.6 | 0.6 | |
| Depression | 0.9 | 1.2 | -0.33 |
| Epilepsy | 0.3 | 0.3 | 0 |
| erectile dysfunction | 0.3 | -0.3 | |
| Fibromyalgia | 0.3 | 0.6 | -1 |
| Functional constipation / chronic idiopathic constipation | 0.6 | 0.8 | -0.33 |
| gallstone disease (gsd) | 0.6 | 0.6 | |
| Glioblastoma | 0.3 | 0.3 | |
| Gout | 0.3 | 0.3 | 0 |
| Graves' disease | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 0.9 | -0.9 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.6 | -0.6 | |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.6 | -1 |
| hyperglycemia | 0.6 | 0.3 | 1 |
| hypertension (High Blood Pressure | 1.7 | 0.9 | 0.89 |
| Hypothyroidism | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.3 | -0.3 | |
| Inflammatory Bowel Disease | 0.8 | 0.8 | |
| Insomnia | 0.6 | 0.6 | |
| Intelligence | 0.3 | -0.3 | |
| Irritable Bowel Syndrome | 0.9 | 1.2 | -0.33 |
| Liver Cirrhosis | 0.6 | 0.9 | -0.5 |
| Long COVID | 1.2 | 0.6 | 1 |
| Low bone mineral density | 0.9 | 0.9 | |
| Lung Cancer | 0.3 | 0.3 | |
| ME/CFS with IBS | 0.2 | 0.2 | |
| Metabolic Syndrome | 2 | 1.5 | 0.33 |
| Mood Disorders | 0.9 | 1.2 | -0.33 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 0.9 | 0.9 | |
| Multiple system atrophy (MSA) | 0.2 | -0.2 | |
| Neuropathy (all types) | 0.3 | -0.3 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.3 | 0.3 | 0 |
| Obesity | 0.3 | 1.1 | -2.67 |
| obsessive-compulsive disorder | 0.3 | 0.3 | |
| Osteoarthritis | 0.3 | -0.3 | |
| Osteoporosis | 0.3 | 0.3 | |
| Parkinson's Disease | 1.1 | 1.1 | |
| Polycystic ovary syndrome | 0.6 | 1.2 | -1 |
| primary biliary cholangitis | 0.3 | -0.3 | |
| Psoriasis | 0.6 | 0.6 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.2 | 1.8 | -0.5 |
| Rosacea | 0.6 | 0.6 | |
| Schizophrenia | 0.6 | 0.3 | 1 |
| scoliosis | 0.3 | -0.3 | |
| sensorineural hearing loss | 0.3 | 0.3 | |
| Sjögren syndrome | 0.3 | 0.3 | |
| Sleep Apnea | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 0.9 | 0.9 | 0 |
| Systemic Lupus Erythematosus | 0.9 | 0.9 | |
| Tic Disorder | 0.2 | 0.2 | |
| Type 1 Diabetes | 0.8 | 0.3 | 1.67 |
| Type 2 Diabetes | 0.6 | 0.6 | 0 |
| Ulcerative colitis | 0.9 | 0.9 | |
| Unhealthy Ageing | 0.6 | 0.6 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.